Researchers discover causes of liver cell scarring
La Jolla (California), October 2
When damaged liver cells are replaced by scar tissue, hepatic fibrosis results. Cirrhosis, liver failure, and even liver cancer can arise as a result of cumulative scarring that, over time, restricts the blood flow to the liver. When the condition is severe, there is no other course of action.
A group of researchers led by corresponding authors David A. Brenner, M.D., president and CEO of Sanford Burnham Prebys, and Tatiana Kisseleva, M.D., Ph.D., professor of surgery at UC San Diego School of Medicine, describe the origin and fate of liver myofibroblasts, the cells that form liver scar tissue, as well as new research suggesting that liver fibrosis can be reversed if the right conditions are present.
“Liver fibrosis is quite common, in part because it can be caused by a number of things that damage the organ but result in scarring rather than healthy repair,” said Brenner, a gastroenterologist and noted liver disease researcher. “Everything from viral hepatitis to excessive alcohol consumption to non-alcoholic fatty liver disease (NAFLD), which is extremely common in the US.”
Indeed, it’s estimated that NAFLD affects approximately 1 billion people worldwide or roughly one-quarter of the human population. Roughly 20 per cent of patients with NAFLD progress to a more serious form called nonalcoholic steatohepatitis (NASH), characterized by inflammation of the liver, fibrosis and cirrhosis.
In their paper, Brenner, Kisseleva and co-authors explain that myofibroblasts are not present in normal, healthy livers, but activate in response to chronic liver injury, such as excessive alcohol consumption. An inflammatory response triggers activation of hepatic stellate cells (aHSC), which transition from relatively scarce, quiescent, vitamin A-storing cells into proliferative myofibroblasts that secrete the scar forming proteins.
These myofibroblasts begin forming a chicken wire of non-functional scar tissue that, over time, thickens and coalesces to clog and choke the liver, cascading to other, life-threatening conditions.
“There are many causes of liver fibrosis and thus, there are no effective therapies currently because most efforts have focused on single targets when the nature of chronic liver injury is incredibly complex,” Brenner said.
An emerging therapeutic approach, said the researchers, is to zero in on disrupting the creation of hepatic myofibroblasts while simultaneously addressing the underlying cause of the liver damage, such as a viral infection or excessive drinking. Do so, the thinking goes, and aHSCs revert to their dormant state and liver fibrosis disappears.
“That means zeroing in on the factors that activate hepatic stellate cells,” said Brenner, signaling pathways that turn them into scar tissue factories.
Recent studies in mouse models and humans have begun to illuminate these cellular and molecular mechanisms. And new single cell technologies and tools like spatial transcriptomics (which can comprehensively characterize tissue organization and architecture at single cell or subcellular resolution) will further the cause.
